Monitor for upcoming clinical milestones for izicopan in ANCA-associated vasculitis and renal indications; the appointment does not alter near-term pipeline catalysts.
Price Chart
Executive Summary
InflaRx announced the appointment of Dr. Gabriela Alperovich as SVP & Global Head of Clinical Development, effective October 1, 2026. Dr. Alperovich brings over 20 years of industry experience in immune-inflammatory renal diseases, including IgA nephropathy and ANCA-associated vasculitis, which aligns with InflaRx's pipeline focus on izicopan. This is a routine leadership hire with no material financial or operational catalyst.
Key Facts
- Dr. Gabriela Alperovich appointed SVP & Global Head of Clinical Development, effective October 1, 2026.
- Dr. Alperovich previously served as Executive Director, Global Clinical Lead for Cardiovascular and Renal at CSL Vifor.
- She has held leadership roles at AbbVie and Bristol-Myers Squibb, with experience in IgA nephropathy, FSGS, and kidney transplant.
- InflaRx is advancing izicopan (oral C5aR inhibitor) for ANCA-associated vasculitis and additional renal indications.
- No financial terms, equity grants, or changes to pipeline timelines were disclosed.
Financial Impact
No financial impact disclosed; routine executive hire.
Risk Factors
- No immediate change to pipeline execution risk or financial outlook.
- Clinical development timelines for izicopan remain subject to regulatory and enrollment uncertainties.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3372778 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 6-K | $1.56 | awaiting T+20 | — | $1.58 (+0.96%) |
Oct 22, 2026 4d ago | Press Release | $1.53 | awaiting T+20 | — | $1.58 (+2.94%) |
Oct 2, 2026 24d ago | Press Release | $1.72 | awaiting T+20 | — | $1.58 (−8.43%) |
Oct 1, 2026 25d ago | Press Release | $1.71 | awaiting T+20 | — | $1.58 (−7.89%) |
Aug 14, 2026 10w ago | 424B5 | $2.07 $2.02 | ▲ +2.42% | ▲ +0.44% | $1.58 (+23.91%) |
Aug 13, 2026 10w ago | EFFECT | $2.01 $2.09 | ▼ −3.98% | ▼ −5.73% | $1.58 (+21.64%) |
Aug 6, 2026 11w ago | 6-K | $1.72 $2.23 | ▲ +29.65% | ▲ +29.05% | $1.58 (−8.43%) |
Jun 30, 2026 16w ago | 6-K | $2.33 $1.65 | ▼ −29.18% | ▼ −27.00% | $1.58 (−32.40%) |
Jun 30, 2026 16w ago | Press Release | $2.24 $1.70 | ▼ −24.11% | ▼ −23.08% | $1.58 (−29.69%) |
May 6, 2026 24w ago | 424B5 | $2.65 $2.06 | ▲ +22.26% | ▲ +25.40% | $1.58 (+40.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers